BACKGROUND AND AIMS: CXCL5 (chemokine [C-X-C motif] ligand 5, also known as epithelial neutrophil-activating peptide 78 [ENA78]) belongs to the CXC chemokine family and has been shown to have promitotic effects on hepatocytes. The aim of our study was to assess CXCL5 plasma levels in patients with chronic liver disease. METHODS: CXCL5 plasma levels were measured in 111 patients with chronic liver disease and 98 healthy controls. The gene expression of CXCL5 and its main receptor, CXC receptor-2, were also determined in liver biopsies from 46 patients. RESULTS: CXCL5 levels were correlated with clinical presentation, laboratory parameters, and liver histology. Plasma CXCL5 levels in patients with liver cirrhosis were lower than those in healthy controls, and correlated with hepatic biosynthetic capacity, Child-Pugh and model for end-stage liver disease scores. Patients with hepatic necroinflammation and fibrosis on liver histology showed lower plasma CXCL5 levels. In patients with typical clinical complications of cirrhosis, CXCL5 levels were found to be decreased. Intrahepatically, CXCL5 expression was increased in patients with advanced fibrosis and cirrhosis. The isolation of different cellular compartments from mouse livers suggested that hepatic stellate cells and sinusoidal endothelial cells are the main sources of hepatic CXCL5. CONCLUSIONS: Plasma CXCL5 levels are lower in patients with chronic liver disease, suggesting that CXCL5 might be involved in the pathogenesis of chronic liver disease. CXCL5 could serve as an additional biomarker for hepatic necroinflammation and fibrosis.
BACKGROUND AND AIMS: CXCL5 (chemokine [C-X-C motif] ligand 5, also known as epithelial neutrophil-activating peptide 78 [ENA78]) belongs to the CXC chemokine family and has been shown to have promitotic effects on hepatocytes. The aim of our study was to assess CXCL5 plasma levels in patients with chronic liver disease. METHODS:CXCL5 plasma levels were measured in 111 patients with chronic liver disease and 98 healthy controls. The gene expression of CXCL5 and its main receptor, CXC receptor-2, were also determined in liver biopsies from 46 patients. RESULTS:CXCL5 levels were correlated with clinical presentation, laboratory parameters, and liver histology. Plasma CXCL5 levels in patients with liver cirrhosis were lower than those in healthy controls, and correlated with hepatic biosynthetic capacity, Child-Pugh and model for end-stage liver disease scores. Patients with hepatic necroinflammation and fibrosis on liver histology showed lower plasma CXCL5 levels. In patients with typical clinical complications of cirrhosis, CXCL5 levels were found to be decreased. Intrahepatically, CXCL5 expression was increased in patients with advanced fibrosis and cirrhosis. The isolation of different cellular compartments from mouse livers suggested that hepatic stellate cells and sinusoidal endothelial cells are the main sources of hepatic CXCL5. CONCLUSIONS: Plasma CXCL5 levels are lower in patients with chronic liver disease, suggesting that CXCL5 might be involved in the pathogenesis of chronic liver disease. CXCL5 could serve as an additional biomarker for hepatic necroinflammation and fibrosis.
Authors: Frank Tacke; Georg Brabant; Elmar Kruck; Rüdiger Horn; Patrick Schöffski; Hartmut Hecker; Michael P Manns; Christian Trautwein Journal: J Hepatol Date: 2003-04 Impact factor: 25.083
Authors: Henning W Zimmermann; Sebastian Seidler; Jacob Nattermann; Nikolaus Gassler; Claus Hellerbrand; Alma Zernecke; Jens J W Tischendorf; Tom Luedde; Ralf Weiskirchen; Christian Trautwein; Frank Tacke Journal: PLoS One Date: 2010-06-10 Impact factor: 3.240
Authors: Frank Tacke; Patrick Schöffski; Christian Trautwein; Tom Luedde; Arnold Ganser; Michael P Manns; Mario von Depka Journal: Blood Coagul Fibrinolysis Date: 2003-06 Impact factor: 1.276
Authors: X Feng; P Scheinberg; L Samsel; O Rios; J Chen; J P McCoy; W Ghanima; J B Bussel; N S Young Journal: J Thromb Haemost Date: 2012-08 Impact factor: 5.824
Authors: Fatjon Leti; Christophe Legendre; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano Journal: Transl Res Date: 2017-09-19 Impact factor: 7.012
Authors: María Martínez-Esparza; María Tristán-Manzano; Antonio J Ruiz-Alcaraz; Pilar García-Peñarrubia Journal: World J Gastroenterol Date: 2015-11-07 Impact factor: 5.742
Authors: Henning W Zimmermann; Sebastian Seidler; Nikolaus Gassler; Jacob Nattermann; Tom Luedde; Christian Trautwein; Frank Tacke Journal: PLoS One Date: 2011-06-22 Impact factor: 3.240
Authors: M Sadeghi; I Lahdou; H Oweira; V Daniel; P Terness; J Schmidt; K-H Weiss; T Longerich; P Schemmer; G Opelz; A Mehrabi Journal: Br J Cancer Date: 2015-08-13 Impact factor: 7.640
Authors: H I El Hajj; A Vluggens; P Andreoletti; K Ragot; S Mandard; S Kersten; H R Waterham; G Lizard; R J A Wanders; J K Reddy; Mustapha Cherkaoui-Malki Journal: Endocrinology Date: 2012-04-16 Impact factor: 4.736